Accordingly, a competitive inhibitor (CPP‐S1 peptide) of PD‐L1 palmitoylation was developed, which reduces PD‐L1 expression in tumor cells and enhances T‐cell immunity against MC38 tumor [17]. This evidence concerns the gene CD274 and neoplasm.